![PDF) A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis | Lars Lööf - Academia.edu PDF) A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis | Lars Lööf - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/42244796/mini_magick20190217-5560-tngbpv.png?1550474785)
PDF) A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis | Lars Lööf - Academia.edu
![Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease. | Semantic Scholar Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e47fb9702c40dca3ba4517eedeb8f16eadba2360/4-Table5-1.png)
Significance of serum and bile tumor markers in the diagnostic approach of patients with malignant pancreatobiliary disease. | Semantic Scholar
![Frontiers | Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study Frontiers | Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study](https://www.frontiersin.org/files/Articles/829407/fonc-12-829407-HTML-r1/image_m/fonc-12-829407-g001.jpg)
Frontiers | Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study
![Table 2 from Serum CEA, CA125, CA19-9, and CA724 levels for the diagnosis and staging of cholangiocarcinoma | Semantic Scholar Table 2 from Serum CEA, CA125, CA19-9, and CA724 levels for the diagnosis and staging of cholangiocarcinoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/dae0860100b99d0263a142e9992e453150e5307b/3-Table2-1.png)
Table 2 from Serum CEA, CA125, CA19-9, and CA724 levels for the diagnosis and staging of cholangiocarcinoma | Semantic Scholar
![Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41575-020-0310-z/MediaObjects/41575_2020_310_Fig8_HTML.png)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology
![PDF] Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma | Semantic Scholar PDF] Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/942919bec9429e21c4d8ed2b634a865a13da7cad/3-Table2-1.png)
PDF] Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma | Semantic Scholar
![Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target - eBioMedicine Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target - eBioMedicine](https://www.thelancet.com/cms/attachment/86f02d41-2c36-4dad-8b14-da8436e0b42d/gr1_lrg.jpg)
Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target - eBioMedicine
![Cancers | Free Full-Text | Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma—What Do We Already Know Cancers | Free Full-Text | Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma—What Do We Already Know](https://www.mdpi.com/cancers/cancers-14-01493/article_deploy/html/images/cancers-14-01493-g003.png)
Cancers | Free Full-Text | Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma—What Do We Already Know
![Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41575-020-0310-z/MediaObjects/41575_2020_310_Fig1_HTML.png)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology
![CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma | Scientific Reports CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-017-17175-7/MediaObjects/41598_2017_17175_Fig1_HTML.jpg)
CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma | Scientific Reports
![Frontiers | Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology Frontiers | Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology](https://www.frontiersin.org/files/MyHome%20Article%20Library/768009/768009_Thumb_400.jpg)
Frontiers | Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology
![Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41575-020-0310-z/MediaObjects/41575_2020_310_Fig4_HTML.png)